Company intelligence / Profile preview

Guilin China Resources Tianhe Pharmaceutical

Guilin, Guangxi Zhuang Autonomous Region, Chinaen.crc.com.cn ↗

Ownership: Private
Development stage: Other

Overview

The company has a leading position in external application Chinese medicines for orthopedics. Its core product, Jinbuhuan Gutong Capsule, reached Phase 2 clinical trials for knee osteoarthritis. Flagship commercial products include the best-selling topical patch for hyperostosis and a well-established ointment for osteoarthritis. The company was acquired by CR Sanjiu in February 2024 to expand its orthopedics portfolio.

Therapeutic areas: RheumatologyNeurologyHematology
Modalities: Herbal medicineSmall moleculeTopical formulation
Industry: Biotech

Partnerships

none publicly disclosed; now part of CR Sanjiu/China Resources Group ecosystem

Beyond the preview

Go deeper on Guilin China Resources Tianhe Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guilin China Resources Tianhe Pharmaceutical.

Explore the full profile